Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
AVIR Stock Chart & Stats
$5.33
$0.04(1.19%)
At close: 4:00 PM EST
$5.33
$0.04(1.19%)
Day’s Range― - ―
52-Week Range$2.46 - $6.45
Previous CloseN/A
Volume180.19K
Average Volume (3M)585.86K
Market Cap
$443.77M
Enterprise Value$329.78M
Total Cash (Recent Filing)$301.83M
Total Debt (Recent Filing)$843.00K
Price to Earnings (P/E)―
Beta0.51
Next Earnings
May 13, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding79,672,080
10 Day Avg. Volume705,776
30 Day Avg. Volume585,860
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.30
Enterprise Value/Ebitda-1.86
Forecast
1Y Price Target
$8.00Price Target Upside50.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial AnalysisUse of a modified intent-to-treat analysis could increase observed effectiveness of the investigational hepatitis C regimen by excluding randomized patients who never received dosing, improving the chance of demonstrating superiority versus the standard treatment.
Pivotal Trial OutcomesTop-line results from two late-stage global trials will determine whether the hepatitis C therapy can compete with current treatments and could meaningfully influence investor sentiment if results favor the experimental regimen.
Regulatory PathwayAnalyst notes that the company plans to file a regulatory application for the hepatitis C combination if pivotal trials are successful, creating a potential catalyst for valuation uplift upon a formal filing decision.
Bears Say
Development Funding RiskPressure on financial flexibility could limit resources available for clinical development or delay regulatory activities if additional funding is not secured.
Financial PerformanceA reported net loss slightly larger than analyst estimates may pressure the company's financial flexibility and weigh on investor confidence.
Funding And Dilution RiskLarger-than-expected losses could increase the likelihood of a capital raise, which may lead to shareholder dilution and put downward pressure on the stock.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals’s price range in the past 12 months?
Atea Pharmaceuticals lowest stock price was $2.46 and its highest was $6.45 in the past 12 months.
What is Atea Pharmaceuticals’s market cap?
Atea Pharmaceuticals’s market cap is $443.77M.
When is Atea Pharmaceuticals’s upcoming earnings report date?
Atea Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 48 days.
How were Atea Pharmaceuticals’s earnings last quarter?
Atea Pharmaceuticals released its earnings results on Mar 05, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.485 by -$0.085.
Is Atea Pharmaceuticals overvalued?
According to Wall Street analysts Atea Pharmaceuticals’s price is currently Undervalued.
Does Atea Pharmaceuticals pay dividends?
Atea Pharmaceuticals does not currently pay dividends.
What is Atea Pharmaceuticals’s EPS estimate?
Atea Pharmaceuticals’s EPS estimate is -0.56.
How many shares outstanding does Atea Pharmaceuticals have?
Atea Pharmaceuticals has 79,672,080 shares outstanding.
What happened to Atea Pharmaceuticals’s price movement after its last earnings report?
Atea Pharmaceuticals reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.485. Following the earnings report the stock price went up 11.132%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals?
Currently, no hedge funds are holding shares in AVIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atea Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (50.09% Upside)
$8.00 (50.09% Upside)
Blogger Sentiment
Bullish
AVIR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 57.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.0%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.98%
12-Months-Change
Fundamentals
Return on Equity
-46.34%
Trailing 12-Months
Asset Growth
-32.16%
Trailing 12-Months
Company Description
Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed substantial forward momentum: the HCV Phase III program is advancing to expected topline readouts this year, Phase II data show high efficacy (95% mITT, 98% per-protocol), a well-capitalized balance sheet ($301.8M) with runway through 2027, and a promising new HEV program (AT-587) moving into first-in-human studies. Notable risks include a growing HCV treatment gap, competitive/pricing pressures, regional regulatory endpoint differences, concentrated prescriber dynamics, and the early-stage nature of the HEV program; milestone and royalty obligations to Merck will affect post-launch economics. On balance, the positives—clinical progress, strong efficacy signals, commercial planning and financial resources—outweigh the risks communicated on the call.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$8.00
▲(50.09% Upside)
Technical Analysis
Ownership Overview
11.11% Insiders
15.74% Mutual Funds
21.30% Other Institutional Investors
41.04% Public Companies and
Individual Investors